{"organizations": [], "uuid": "a84d11486b2837f40ccc13fce15c6da0e727ca2b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-esperion-therapeutics-says-bempedo/brief-esperion-therapeutics-says-bempedoic-acid-observed-to-be-safe-well-tolerated-in-phase-3-study-idUSB8N1KT00N", "country": "US", "domain_rank": 408, "title": "BRIEF-Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.921, "site_type": "news", "published": "2018-03-07T20:45:00.000+02:00", "replies_count": 0, "uuid": "a84d11486b2837f40ccc13fce15c6da0e727ca2b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-esperion-therapeutics-says-bempedo/brief-esperion-therapeutics-says-bempedoic-acid-observed-to-be-safe-well-tolerated-in-phase-3-study-idUSB8N1KT00N", "ord_in_thread": 0, "title": "BRIEF-Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "negative"}, {"name": "esperion", "sentiment": "negative"}, {"name": "esperion therapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID\n* ESPERION THERAPEUTICS SAYS PHASE 3 STUDY OF BEMPEDOIC ACID MET PRIMARY ENDPOINT WITH 28% LOW DENSITY LIPOPROTEIN CHOLESTEROL LOWERING\n* ESPERION THERAPEUTICS SAYS BEMPEDOIC ACID OBSERVED TO BE SAFE AND WELL-TOLERATED IN THE PHASE 3 STUDY Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T20:45:00.000+02:00", "crawled": "2018-03-08T17:38:10.036+02:00", "highlightTitle": ""}